Murali R - Search Results

1

HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.

Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. Guillemard V, et al. Among authors: murali r. DNA Cell Biol. 2005 Jun;24(6):350-8. doi: 10.1089/dna.2005.24.351. DNA Cell Biol. 2005. PMID: 15941387

2

Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation.

Zhang X, Piatier-Tonneau D, Auffray C, Murali R, Mahapatra A, Zhang F, Maier CC, Saragovi H, Greene MI. Zhang X, et al. Among authors: murali r. Nat Biotechnol. 1996 Apr;14(4):472-5. doi: 10.1038/nbt0496-472. Nat Biotechnol. 1996. PMID: 9630922

3

The synthetic CD4 exocyclic CDR3.AME(82-89) inhibits NF-kappaB nuclear translocation, HIV-1 promoter activation, and viral gene expression.

Roland J, Berezov A, Greene MI, Murali R, Piatier-Tonneau D, Devaux C, Briant L. Roland J, et al. Among authors: murali r. DNA Cell Biol. 1999 Nov;18(11):819-28. doi: 10.1089/104454999314818. DNA Cell Biol. 1999. PMID: 10595395

4

Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.

Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R. Park BW, et al. Among authors: murali r. Nat Biotechnol. 2000 Feb;18(2):194-8. doi: 10.1038/72651. Nat Biotechnol. 2000. PMID: 10657127

5

HER2/neu: mechanisms of dimerization/oligomerization.

Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. Brennan PJ, et al. Among authors: murali r. Oncogene. 2000 Dec 11;19(53):6093-101. doi: 10.1038/sj.onc.1203967. Oncogene. 2000. PMID: 11156522 Review. No abstract available.

6

Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.

Berezov A, Zhang HT, Greene MI, Murali R. Berezov A, et al. Among authors: murali r. J Med Chem. 2001 Aug 2;44(16):2565-74. doi: 10.1021/jm000527m. J Med Chem. 2001. PMID: 11472210

7

HER2/Neu: mechanisms of dimerization/oligomerization.

Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. Brennan PJ, et al. Among authors: murali r. Oncogene. 2002 Jan 10;21(2):328. doi: 10.1038/sj.onc.1205119. Oncogene. 2002. PMID: 11840330

8

Disabling receptor ensembles with rationally designed interface peptidomimetics.

Berezov A, Chen J, Liu Q, Zhang HT, Greene MI, Murali R. Berezov A, et al. Among authors: murali r. J Biol Chem. 2002 Aug 2;277(31):28330-9. doi: 10.1074/jbc.M202880200. Epub 2002 May 14. J Biol Chem. 2002. PMID: 12011054 Free article.

9

Study of disabling T-cell activation and inhibiting T-cell-mediated immunopathology reveals a possible inverse agonist activity of CD4 peptidomimetics.

Horie T, Shen Y, Kajino K, Gaubin M, Bonomi G, Mani JC, Berezov A, Piatier-Tonneau D, Guardiola J, Hillard B, Rostami A, Greene M, Murali R. Horie T, et al. Among authors: murali r. Exp Mol Pathol. 2002 Oct;73(2):93-103. doi: 10.1006/exmp.2002.2444. Exp Mol Pathol. 2002. PMID: 12231211

10

Structure-based approaches to inhibition of erbB receptors with peptide mimetics.

Berezov A, Greene MI, Murali R. Berezov A, et al. Among authors: murali r. Immunol Res. 2003;27(2-3):303-8. doi: 10.1385/IR:27:2-3:303. Immunol Res. 2003. PMID: 12857977 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

544 results

Search Page

Filters